SWP
BBIO icon

Stratos Wealth Partners’s BridgeBio Pharma BBIO Stock Holding History

Stratos Wealth Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$492K Sell
6,603
-37
-0.6% -$2.59K 0.01% 1155
2026
Q1 		$493K Sell
6,640
-100
-1% -$7.25K 0.01% 1071
2025
Q4 		$516K Hold
6,740
– – 0.01% 1034
2025
Q3 		$350K Buy
+6,740
New +$329K ﹤0.01% 1177

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Stratos Wealth Partners's BBIO Position: Q2 2026 in Review

Stratos Wealth Partners reduced its BridgeBio Pharma (BBIO) stake by 0.56% in Q2 2026, selling an estimated $2.59K and leaving 6,603 shares worth $492K. The position accounts for 0.01% of the portfolio, ranked #1155.

Stratos Wealth Partners first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $516K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Stratos Wealth Partners held 6,603 shares of BridgeBio Pharma worth $492K as of Q2 2026.
  • Stratos Wealth Partners sold 37 BridgeBio Pharma shares in Q2 2026, an estimated $2.59K.
  • BridgeBio Pharma made up 0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1155 holding.
  • Stratos Wealth Partners first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Stratos Wealth Partners's BridgeBio Pharma position peaked at $516K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.